艾尔建在2015年前购买Naurex时,花费超过了5.6亿美元,当时的期望是加强公司长期增长前景,当时艾尔建的股价接近最高点331美元。然而试验惨败,艾尔建的股票在盘后交易中下跌约5%。(新浪医药编译/范东东)
文章参考来源:
1、Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
2、Allergan’s $560M buyout deal just led to a PhIII debacle as another depression drug goes down to bitter defeat
3、Allergan’s Depression Treatment Will Not Hit Endpoints in Late-Stage Trial
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。